These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 34651585)
21. A Primer on the Evolution of Aducanumab: The First Antibody Approved for Treatment of Alzheimer's Disease. Mukhopadhyay S; Banerjee D J Alzheimers Dis; 2021; 83(4):1537-1552. PubMed ID: 34366359 [TBL] [Abstract][Full Text] [Related]
22. Alzheimer's disease: the controversial approval of Aducanumab. Tagliavini F; Tiraboschi P; Federico A Neurol Sci; 2021 Aug; 42(8):3069-3070. PubMed ID: 34322762 [No Abstract] [Full Text] [Related]
23. Possible Consequences of the Approval of a Disease-Modifying Therapy for Alzheimer Disease. Musiek ES; Morris JC JAMA Neurol; 2021 Feb; 78(2):141-142. PubMed ID: 33252672 [No Abstract] [Full Text] [Related]
24. Aducanumab: A look two years after its approval. Torres A; Camargo L; López N Biomedica; 2024 May; 44(Sp. 1):42-46. PubMed ID: 39079148 [TBL] [Abstract][Full Text] [Related]
27. [Aducanumab and Alzheimer's disease: a critical reflection.]. Vanacore N; Blasimme A; Canevelli M Recenti Prog Med; 2021; 112(7):495-498. PubMed ID: 34263875 [TBL] [Abstract][Full Text] [Related]
28. Biogen's aducanumab raises hope that Alzheimer's can be treated at its source. Patel KR Manag Care; 2015 Jun; 24(6):19. PubMed ID: 26182718 [No Abstract] [Full Text] [Related]
29. Amyloid Cascade into Clarity. Weitz TM; Town T Immunity; 2016 Oct; 45(4):717-718. PubMed ID: 27760336 [TBL] [Abstract][Full Text] [Related]
30. Aducanumab (Marketed as Aduhelm) Approval Is Likely Based on Misinterpretation of PET Imaging Data. Høilund-Carlsen PF; Alavi A J Alzheimers Dis; 2021; 84(4):1457-1460. PubMed ID: 34657891 [TBL] [Abstract][Full Text] [Related]
31. Vessels Sing Their ARIAs: The Role of Vascular Amyloid in the Age of Aducanumab. Sveikata L; Charidimou A; Viswanathan A Stroke; 2022 Jan; 53(1):298-302. PubMed ID: 34905943 [TBL] [Abstract][Full Text] [Related]
32. Aducanumab and the Business of Alzheimer Disease-Some Choice. Karlawish J JAMA Neurol; 2021 Nov; 78(11):1303-1304. PubMed ID: 34410302 [No Abstract] [Full Text] [Related]
33. The Problem of Aducanumab for the Treatment of Alzheimer Disease. Alexander GC; Karlawish J Ann Intern Med; 2021 Sep; 174(9):1303-1304. PubMed ID: 34138642 [No Abstract] [Full Text] [Related]
34. Evaluation of Aducanumab for Alzheimer Disease: Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility. Alexander GC; Emerson S; Kesselheim AS JAMA; 2021 May; 325(17):1717-1718. PubMed ID: 33783469 [No Abstract] [Full Text] [Related]
35. Alzheimer disease neuropathology in a patient previously treated with aducanumab. Plowey ED; Bussiere T; Rajagovindan R; Sebalusky J; Hamann S; von Hehn C; Castrillo-Viguera C; Sandrock A; Budd Haeberlein S; van Dyck CH; Huttner A Acta Neuropathol; 2022 Jul; 144(1):143-153. PubMed ID: 35581440 [TBL] [Abstract][Full Text] [Related]
37. Aducanumab for Alzheimer's Disease: Summarized Data From EMERGE, ENGAGE, and PRIME Studies. Yuksel JM; Noviasky J; Britton S Sr Care Pharm; 2022 Aug; 37(8):329-334. PubMed ID: 35879846 [No Abstract] [Full Text] [Related]
39. Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019. Knopman DS; Jones DT; Greicius MD Alzheimers Dement; 2021 Apr; 17(4):696-701. PubMed ID: 33135381 [TBL] [Abstract][Full Text] [Related]
40. Co-pathology may impact outcomes of amyloid-targeting treatments: clinicopathological results from two patients treated with aducanumab. VandeVrede L; La Joie R; Horiki S; Mundada NS; Koestler M; Hwang JH; Ljubenkov PA; Rojas JC; Rabinovici GD; Boxer AL; Seeley WW Acta Neuropathol; 2023 Nov; 146(5):777-781. PubMed ID: 37725166 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]